Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors

Invited Commentary: Understanding Bias Amplification

(2011) J. Pearl   AMERICAN JOURNAL OF EPIDEMIOLOGY

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

(2011) E. Imai et al.   DIABETOLOGIA

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Confounding Control in Healthcare Database Research

(2010) M. Alan Brookhart et al.   MEDICAL CARE

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

(2010) Peter C. Austin   PHARMACEUTICAL STATISTICS

A computer case definition for sudden cardiac death

(2009) Cecilia P. Chung et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY